Skip to Content

Cuvitru Approval History

Cuvitru (immune globulin subcutaneous (human)) is indicated as replacement therapy in the treatment of primary humoral immunodeficiency (PI).

FDA approval follows publication of the results of a Phase II/III study of Cuvitru in 74 patients with primary immunodeficiency. Cuvitru was determined safe and effective with a tolerability profile enabling infusions to be administered at higher rates and volumes compared to conventional SC preparations.

Cuvitru is a ready-to-use injection administered via subcutaneous infusion at regular intervals from daily up to every two weeks. Common side effects include infusion site reactions, headache, nausea, fatigue, diarrhea, and vomiting.

Development History and FDA Approval Process for Cuvitru

DateArticle
Sep 14, 2016Approval Shire Announces FDA Approval of Cuvitru [immune globulin subcutaneous (human)] for Primary Immunodeficiency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide